Your CRO’s Assignment Strategy for CRAs Matters!
Monitoring the progress of clinical research is fundamental to obtaining successful outcomes because it ensures that constraints to success are…
Monitoring the progress of clinical research is fundamental to obtaining successful outcomes because it ensures that constraints to success are…
Clinical trials, and in particular oncology studies, can be very complex and often involve multiple parties: Sponsor, CRO (sometimes several…
In this interview, Susanne Picard, Founder & President of SPharm Inc., answers questions about the Canadian regulatory environment and dispels…
In this interview Janet Manzo, Executive Director of the Ontario Cancer Research Ethics Board, discusses the development of a province-wide…
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
In this interview, Marjorie Morrison, CEO of the Canadian Cancer Action Network, talks about the important role patient advocacy groups…
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…